Antithrombotics in Acute Ischemic Stroke - The Clot Thickens

Despite an incidence of over 1.7m in the seven major markets, the thrombolytic Activase (alteplase) is the only drug approved for ischemic stroke outside of Japan and has a three-hour therapeutic window, which means that only a minority of patients are eligible for therapy. Therefore, ischemic stroke is a potentially lucrative target market for pharmaceutical companies. 

Scope

Estimates of the current and future incidence of acute ischemic stroke in the seven major markets 

Discussion of current status of therapy and identification of the unmet needs with greatest commercial potential 

Profiles of antithrombotics being trialed in acute ischemic stroke, analyzing their strengths and weaknesses in this indication 

Comparative assessment of antithrombotics in development for stoke, in relation to alteplase, in terms of satisfaction of unmet need and potential 

Report Highlights

With an estimated incidence of over 1.7m ischemic strokes in 2002 in the seven major markets and high unmet need, with just one drug approved outside of Japan for ischemic stroke, there is significant impetus for companies to trial agents in this indication. 

In terms of developing safe and effective therapies for ischemic stroke, the greatest obstacle lies in extending the therapeutic window from the currently limited three hours to at least 6-12 hours. 

In the absence of regenerative therapy, companies need to look beyond conventional single drug approaches and investigate which combinations of drugs and/or devices can achieve the best possible results in acute ischemic stroke. 

Reasons to Purchase

Identify strategies for increasing the patient potential of antithrombotics in development for stroke 

Identify the unmet needs that exist in the treatment of acute ischemic stroke and the extent that are likely to be met over the coming years 

Understand which antithrombotics currently in development for acute ischemic stroke are the most promising and why 

Publisher: Datamonitor Cardiovascular Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Cardiovascular.html#a74